We are live on ! Find out more
VYNT

Vyant Bio, Inc. Common Stock
VYNT

Delisted

VYNT was delisted on the 12th of May, 2023.

Back to rankings

18 hedge funds and large institutions have $1.73M invested in Vyant Bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more capital invested

Capital invested by funds: $485K → $1.73M (+$1.25M)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

22% less funds holding

Funds holding: 23 → 18 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
18
Holders Change
-5
Holders Change %
-21.74%
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
5
Reduced
3
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$199K
2
BlackRock
BlackRock
New York
+$174K
3
OAM
Oxford Asset Management
United Kingdom
+$113K
4
LI
Leap Investments
Illinois
+$93.4K
5
Millennium Management
Millennium Management
New York
+$51.8K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$22K
2
DM
Diker Management
New York
-$7K
3
UBS Group
UBS Group
Switzerland
-$4.83K
4
PCM
Perkins Capital Management
Minnesota
-$4K
5
TSS
Two Sigma Securities
New York
-$4K

VYNT Hedge Fund Activity: Q4 2019 in Review

18 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2019, worth a combined $1.73M — up 257% from $485K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of VYNT and 6 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $199K. The largest seller was Geode Capital Management, exiting entirely with an estimated $22K sold.

  • 18 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2019, down from 23 in Q3 2019.
  • Funds reported $1.73M of Vyant Bio, Inc. Common Stock stock for Q4 2019, up 257% quarter-over-quarter.
  • 6 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of -5 holders.
  • The largest Vyant Bio, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $199K added.
  • The largest Vyant Bio, Inc. Common Stock seller in Q4 2019 was Geode Capital Management, an estimated $22K sold.

Based on aggregated 13F filings for Q4 2019.